The global Leukemia Screening Market is estimated to be valued at US$ 17.04 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Leukemia screening products include instruments, consumables, and software which are used to screen blood and bone marrow samples for various types of leukemia. Early detection of leukemia plays a vital role in treatment of this cancer.
Market key trends:
Advancements in genomics and high demand for non-invasive screening tests are driving the growth of the leukemia screening market. Genomic tests provide more comprehensive information about leukemia by analyzing multiple genes and their interactions simultaneously. This helps in better diagnosis and selection of targeted treatment. Non-invasive liquid biopsies that detect circulating tumor DNA in blood are gaining popularity as they are easy to perform and can be used for regular monitoring of the disease.
Segment Analysis
The global leukemia screening market is segmented into technique, disease type, end user, and region. Based on technique, the market is categorized into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. The flow cytometry segment dominates the market owing to its widespread adoption for detection and classification of leukemia. Flow cytometry allows rapid multi-parametric analysis of heterogeneous cell populations on the basis of characteristics such as cell size, granularity, and protein expression.
Key Takeaways
The Global Leukemia Screening Market Size was valued at US$ 17.04 Bn in 2023 and is expected to reach US$ 29.23 Bn by 2030, exhibiting a CAGR of 6.4% over the forecast period. The growth of the market can be attributed to the increasing prevalence of leukemia and growing awareness regarding early diagnosis.
Regional Analysis
North America dominated the global leukemia screening market in 2023 and is expected to retain its dominance over the forecast period. High healthcare expenditure, availability of advanced diagnostic techniques, and rising incidence of leukemia are some of the key factors propelling the market growth in North America. Asia Pacific is anticipated to witness the highest CAGR during the forecast period owing to rapidly developing healthcare infrastructure and improving access to diagnosis in densely populated countries such as China and India.
Key players
Key players operating in the leukemia screening market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Illumina, Inc., QIAGEN N.V., Grifols, S.A., Siemens Healthineers AG, Agilent Technologies, Inc., Ortho Clinical Diagnostics, Biocept, Inc., Adaptive Biotechnologies Corporation, Invivoscribe, Inc., and ArcherDX, Inc. These players are focusing on expanding their product portfolios and global footprint through mergers & acquisitions to strengthen their market position.
Read More :https://www.ukwebwire.com/leukemia-screening-market-size/
